References

1.              Kondo, T., S. Ezzat, and S.L. Asa, Pathogenetic mechanisms in thyroid follicular-cell neoplasia. Nat Rev Cancer, 2006. 6(4): p. 292-306.

2.              Lazar, M.A., Thyroid hormone receptors: multiple forms, multiple possibilities. Endocr Rev, 1993. 14(2): p. 184-93.

3.              Hay, R., et al., BRAF mutations in melanocytic lesions and papillary thyroid carcinoma samples identified using melting curve analysis of polymerase chain reaction products. Arch Pathol Lab Med, 2007. 131(9): p. 1361-7.

4.              Ghossein, R., Problems and controversies in the histopathology of thyroid carcinomas of follicular cell origin. Arch Pathol Lab Med, 2009. 133(5): p. 683-91.

5.              Caron, N.R. and O.H. Clark, Papillary thyroid cancer. Curr Treat Options Oncol, 2006. 7(4): p. 309-19.

6.              Wiseman, S.M., et al., Anaplastic transformation of thyroid cancer: review of clinical, pathologic, and molecular evidence provides new insights into disease biology and future therapy. Head Neck, 2003. 25(8): p. 662-70.

7.              Xia, J., et al., beta-Catenin mutation and its nuclear localization are confirmed to be frequent causes of Wnt signaling pathway activation in pilomatricomas. J Dermatol Sci, 2006. 41(1): p. 67-75.

8.              Garcia-Rostan, G., et al., Frequent mutation and nuclear localization of beta-catenin in anaplastic thyroid carcinoma. Cancer Res, 1999. 59(8): p. 1811-5.

9.              Moley, J.F., et al., Surgical management of patients with persistent or recurrent medullary thyroid cancer. J Intern Med, 1998. 243(6): p. 521-6.

10.            Roque, L., et al., Genetic markers in thyroid tumors. Surgery, 1993. 113(5): p. 595-8.

11.            Puxeddu, E. and J.A. Fagin, Genetic markers in thyroid neoplasia. Endocrinol Metab Clin North Am, 2001. 30(2): p. 493-513, x.

12.          McLachlan, S.M. and B. Rapoport, Genetic and epitopic analysis of thyroid   

               peroxidase (TPO) autoantibodies: markers of the human thyroid   

               autoimmune response. Clin Exp Immunol, 1995. 101(2): p. 200-6.

13.          Santoro, M., R.M. Melillo, and A. Fusco, RET/PTC activation in papillary   

               thyroid carcinoma: European Journal of Endocrinology Prize Lecture. Eur J   

               Endocrinol, 2006. 155(5): p. 645-53.

14.          Kebebew, E., et al., Long-term results of reoperation and localizing studies in patients with persistent or recurrent medullary thyroid cancer. Arch Surg, 2000. 135(8): p. 895-901.

15.          Kebebew, E. and O.H. Clark, Medullary thyroid cancer. Curr Treat Options Oncol, 2000. 1(4): p. 359-67.

16.         http://www.myentspecialist.com/images/hns_06.jpg

17.         http://www.auntminnie.com/ScottWilliamsMD2/NucMed/Endocrine Thyroid/I-131%20for%20cancer/images/bulkydz_123_pre_131_post.jpg

18.          http://schools.medphys.ucl.ac.uk/images/radiation/pet_scan1.jpg

19.          Fu, C.C., et al., Tunable Nanowrinkles on Shape Memory Polymer Sheets. Advanced Materials, 2009. 21(44): p. 4472-+.

20.          Nguyen, D., Douglas, T., Qian, K., Norouzi, N., Rasmussen, J., Botzet, S., Lehmann, M., Halverson, K., and Khine, M., Better shrinkage than Shrinky-Dinks. Lag Chip, 2010. DOI: 10.1039/c001082k.